|
|
|
|
|
|
[1]
|
NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 51-66, AND CHARACTERIZATION.
TISSUE=Venom;
DOI=10.1074/jbc.274.20.13752; PubMed=10318778 [NCBI, ExPASy, EBI, Israel, Japan]
Craig A.G.,
Norberg T.,
Griffin D.,
Hoeger C.,
Akhtar M.,
Schmidt K.,
Low W.,
Dykert J.,
Richelson E.,
Navarro V.,
Mazella J.,
Watkins M.,
Hillyard D.R.,
Imperial J.,
Cruz L.J.,
Olivera B.M.;
"Contulakin-G, an O-glycosylated invertebrate neurotensin.";
J. Biol. Chem. 274:13752-13759(1999).
|
[2]
|
THERAPEUTIC USAGE.
DOI=10.1016/S0304-3959(02)00303-2; PubMed=12507705 [NCBI, ExPASy, EBI, Israel, Japan]
Malmberg A.B.,
Gilbert H.,
McCabe R.T.,
Basbaum A.I.;
"Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T.";
Pain 101:109-116(2003).
|
|
|
|
- FUNCTION: Acts as an agonist of neurotensin receptors. It binds to human neurotensin type 1 receptor (hNTR1), rat neurotensin types 1 and 2 receptors and mouse neurotensin type 3 receptor.
- SUBCELLULAR LOCATION: Secreted.
- TISSUE SPECIFICITY: Expressed by the venom duct.
- PTM: O-glycosylated. The glycosylation seems to enhance the affinity to the neurotensin receptors.
- PHARMACEUTICAL: Is under phase II clinical trials under the name CGX-1160 by Cognetix Inc. It is efficacious in a wide range of preclinical pain models (acute, post-surgical, inflammatory, and neuropathic), and is particularly efficacious in models of chronic pain.
- SIMILARITY: Belongs to the contulakin family.
|
|
|
|
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms.
Distributed under the Creative Commons Attribution-NoDerivs License.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Length: 76 AA [This is the length of the unprocessed precursor] |
Molecular weight: 8261 Da [This is the MW of the unprocessed precursor] |
CRC64: D8094EB30C6AAFD4 [This is a checksum on the sequence] |
|
10 20 30 40 50 60
MQTAYWVMVM MMVWIAAPLS EGGKLNDVIR GLVPDDITPQ LILGSLISRR QSEEGGSNAT
70
KKPYILRASD QVASGP
|
Q9XYR5 in FASTA format |
|